Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
08:05pm, Tuesday, 01'st Nov 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, tod
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
04:05pm, Tuesday, 01'st Nov 2022
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
02:11pm, Friday, 21'st Oct 2022 Benzinga
Upgrades
SVB Leerink upgraded the previous rating for Moderna Inc (NASDAQ:MRNA) from Underperform to Market Perform. Moderna earned $5.24 in the second quarter, compared to $6.46 in the year-ago quart
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
11:00am, Thursday, 22'nd Sep 2022 GlobeNewswire Inc.
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
08:05pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel
Revolution Medicines to Participate in Upcoming Investor Conferences
08:05pm, Wednesday, 31'st Aug 2022 GlobeNewswire Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today ann
Revolution Medicines to Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 31'st Aug 2022
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today annou
Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
01:55pm, Tuesday, 30'th Aug 2022 Zacks Investment Research
The consensus price target hints at a 45.4% upside potential for Revolution Medicines, Inc. (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
03:59pm, Friday, 12'th Aug 2022 Benzinga
Altimmune, Inc. (NASDAQ: ALT) jumped 28% to $17.64. B. Riley Securities maintained Altimmune with a Buy and raised the price target from $21 to $26.
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) ju
Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know
01:55pm, Friday, 12'th Aug 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.9% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is quest
Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates
10:15pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
08:02pm, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development
Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates
07:33pm, Tuesday, 09'th Aug 2022
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
04:02pm, Thursday, 28'th Jul 2022
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today
$10 Million Bet On This Financial Services Stock? 3 Stocks Insiders Are Buying
02:30pm, Tuesday, 26'th Jul 2022 Benzinga
Although US stocks closed mixed on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock
